Patent Overview
A cardiovascular formulation dossier positioned around coronary disease, angina management, and combination-therapy discussion.
Indication: Coronary Heart Disease Angina Pectoris Direction, Cardiovascular Supportive Treatment Research, Joint Development Communication
Principle and Advantage
Guanxinling is most easily understood by partners as an 'asset for symptom management and combination therapy in common cardiovascular diseases.' Its value lies not in replacing standard Western medicines, but in providing a complementary information gateway to existing anti-anginal, lipid-lowering, and antiplatelet pathways.
Scientific Basis: Activating Blood Circulation and Removing Blood Stasis, Balancing Deficiency and Excess, Integrated Traditional Chinese and Western Medicine Approach to Cardiovascular Disease Treatment
- The cardiovascular field is mature, making it easy to quickly establish a collaborative discussion context.
- It can serve as a traditional Chinese medicine composition asset in the common disease area, rather than a highly niche project.
- It has a broad clinical application scope; the package insert already mentions related areas such as hypertension and cerebral infarction.
Market Context
Market reference：China cardiovascular burden: Approx. 300M; Existing drug baseline: Nitrates / Statins / Antiplatelets
- The cardiovascular track is mature, making it easier for partners and investors to quickly understand the clinical value and commercial context.
- This composition can be positioned around 'symptom management + supplementary combination regimen,' with a clear narrative.
- It is suitable for extending into related areas such as hypertension and cerebral infarction, which are also cardiovascular and cerebrovascular conditions.
Nitroglycerin
Nitrate · Common basic medications for angina attacks and symptom relief.
This asset is more suitable for supplementing existing symptom management rather than replacing basic Western medicines.
Statins
Lipid-lowering therapy · Basic drug categories for long-term management of coronary heart disease.
The package insert incorporates it into the current treatment context.
Antiplatelet therapy
Thrombosis-risk management · A common pathway in secondary prevention and combination therapy for coronary heart disease.
Used to help partners understand the complementary positioning of this asset.
Related Books
Collected Medical Experience of Pei Zhengxue
Collected Medical Experiences of Professor Pei Zhengxue / Compiled and authored by Pei Zhengxue Lanzhou: Gansu Science a.
Cooperation
Suitable for organizing cardiovascular-related materials, facilitating joint treatment communication, and discussing asset portfolios.
This page is for academic exchange and collaboration reference and does not constitute medical advice, product marketing, or efficacy claims.